Bupropion News and Research

RSS
Researchers study quality, effectiveness and safety of generic drugs used to treat depression

Researchers study quality, effectiveness and safety of generic drugs used to treat depression

IQWiG completes first health economic evaluation

IQWiG completes first health economic evaluation

Study assesses risk of psychiatric events in patients prescribed smoking cessation drugs

Study assesses risk of psychiatric events in patients prescribed smoking cessation drugs

Depressed smokers may benefit from mood management interventions

Depressed smokers may benefit from mood management interventions

Smokers with a history of major depressive disorder (MDD) taking varenicline have significantly higher likelihood of quitting smoking than placebo

Smokers with a history of major depressive disorder (MDD) taking varenicline have significantly higher likelihood of quitting smoking than placebo

Smokers who try e-cigarettes to quit are younger and more motivated to quit, study finds

Smokers who try e-cigarettes to quit are younger and more motivated to quit, study finds

Eisai submits BELVIQ NDS with Health Canada

Eisai submits BELVIQ NDS with Health Canada

Smokers trying to quit will have better experience with varenicline, study finds

Smokers trying to quit will have better experience with varenicline, study finds

Orexigen reports progress with FDA on faster path to Contrave NDA resubmission

Orexigen reports progress with FDA on faster path to Contrave NDA resubmission

Prevention is better than cure for smoking in young people

Prevention is better than cure for smoking in young people

BCPR, Orexigen partner to accelerate patient enrollment for Contrave obesity Light Study

BCPR, Orexigen partner to accelerate patient enrollment for Contrave obesity Light Study

Behavioural support programme to make TB patients quit smoking receives BUPA Foundation prize

Behavioural support programme to make TB patients quit smoking receives BUPA Foundation prize

FTC votes to approve Watson's acquisition of Actavis

FTC votes to approve Watson's acquisition of Actavis

Enrollment complete in Euthymics’ amitifadine phase 2b/3a trial for major depressive disorder

Enrollment complete in Euthymics’ amitifadine phase 2b/3a trial for major depressive disorder

Orexigen Therapeutics reports net loss of $16.7 million for second quarter 2012

Orexigen Therapeutics reports net loss of $16.7 million for second quarter 2012

New insight into use and awareness of electronic cigarettes

New insight into use and awareness of electronic cigarettes

Genetics can predict success of smoking cessation and need for medications

Genetics can predict success of smoking cessation and need for medications

Orexigen reports net loss of $10.4 million for first quarter 2012

Orexigen reports net loss of $10.4 million for first quarter 2012

March issue of NeuroPerspective reviews therapeutics for ADHD

March issue of NeuroPerspective reviews therapeutics for ADHD

Weight gain or loss may also depend on medicines taken

Weight gain or loss may also depend on medicines taken

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.